EXANTA
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stroke Prevention in Patients With Atrial Fibrillation
Conditions
Stroke Prevention in Patients With Atrial Fibrillation
Trial Timeline
Aug 1, 1999 → Apr 1, 2006
NCT ID
NCT00206063About EXANTA
EXANTA is a phase 2 stage product being developed by AstraZeneca for Stroke Prevention in Patients With Atrial Fibrillation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00206063. Target conditions include Stroke Prevention in Patients With Atrial Fibrillation.
What happened to similar drugs?
13 of 20 similar drugs in Stroke Prevention in Patients With Atrial Fibrillation were approved
Approved (13) Terminated (6) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00206089 | Phase 3 | Terminated |
| NCT00206063 | Phase 2 | Terminated |
Competing Products
20 competing products in Stroke Prevention in Patients With Atrial Fibrillation